About US
Contact us
-
J&J and Actelion reportedly take complicated deal to Swiss regulator for rulingThere is evidence that Actelion and Johnson & Johnson are edging closerto a deal to give the U.S. drugmaker control of the Swiss biotech, sort of. Citing a report in the Swiss newspaper Tages-Anz2017/1/25
-
Applying Digital Technologies to Profit from Change in the Pharma IndustryPharmaceutical companies are increasingly challenged to keep pace with the evolving demands of patients, physicians and payors. In particular, patients’ desires to be more involved in their treatments2017/1/24
-
With backing from cancer bigwigs, VP Biden reportedly eyes drug prices as part of new nonprofit workAfter finishing eight years as vice president and a stint as Cancer Moonshotguru, Joe Biden plans to head up a new nonprofit to work on cancer issues—and tackling high drug prices is one of them. Bid2017/1/24
-
Greek prosecutors raid Novartis offices, disclose wide-ranging probe into bribery allegationsGreek officialsannouncedTuesday that they are investigating Novartis for bribery in the wake of local media reports raising questions about the company. It is the fourth set of bribery allegations aga2017/1/23
-
The FDA's promo police slap four more pharmas in year-end enforcement spreeThe FDA’s promotional enforcement squad wasn’t very active in 2016—until December, that is. Since the beginning of the month, the Office of Prescription Drug Promotion has cited six drugmakers for ove2017/1/22
-
It's the same song, but a brand-new verse for 2017's drug-pricing debateWe won’t surprise anyone by saying that Topic No. 1 in pharma this year was drug pricing. We’ll give you one guess as to whether 2017 will be more of the same. The advent of a Trump Administration es2017/1/20
-
UPDATED: Senate proposes incentivizing generic drugmakers to help control price hikesAfter a yearlong investigation into rising drug prices, the U.S. Senate Special Committee on Aging has released areportthat seeks to provide solutions to a tough conundrum: Legislators don’t want the2017/1/20
-
Medicare Part B changes are dead and that’s good for pharma: reportEarlier this year, the Centers for Medicare and Medicaid Services (CMS) unveiled a plan to test a new payment model for Medicare Part B that would incentivize healthcare providers to use low-cost drug2017/1/19
-
U.K. authorities say Actavis broke competition law with 'excessive and unfair prices' on a genericFor the second time this month, officials in the U.K. there are taking issue with huge price hikes. The country's Competition and Markets Authority, which earlier this month hit Pfizer with a $108 mil2017/1/19
-
Pfizer finally convinces FDA to pull black-box warning on Chantix for psychotic side effectsSeven years after safety concerns altered the trajectory of Pfizer’s stop-smoking med Chantix, the FDA haspulledits black-box warning from the drug’s label. FDA officials removed the warning after2017/1/18